NanoPass’s intradermal injection platform proven to sustain COVID-19 vaccine antibodies using 1/15 of the dose reports Chinese Institute of Medical BiologyAdela Ance2022-02-07T14:48:09+00:00February 7th, 2022|Read More
NanoPass’s intradermal delivery platform used in Emergex’s next generation COVID-19 vaccination studyAdela Ance2022-01-26T15:45:55+00:00January 26th, 2022|Read More
NanoPass and M2N enter strategic development & foundry agreementAdela Ance2021-12-23T07:16:15+00:00December 22nd, 2021|Read More
NanoPass and AMP launch MicronJet®600 for aesthetics in the USAAdela Ance2021-12-19T13:55:21+00:00November 23rd, 2021|Read More
NanoPass Is Joining Forces with Pharma Partners in The Fight Against The COVID-19 PandemicGal Admati2021-01-26T09:29:54+00:00April 20th, 2020|Read More
FILLMED and NanoPass Launch NANOSOFT™ Microneedles for AestheticsGal Admati2020-06-03T04:13:31+00:00April 3rd, 2019|Read More
IDRI & NanoPass Sign Agreement to Develop an Intradermal rvRNA-Based Zika Virus Vaccinemonimono2020-06-03T04:19:41+00:00March 5th, 2017|Read More
NanoPass Technologies to Present Newly Released Data on Intradermal Flu Vaccinationmonimono2020-06-03T04:24:54+00:00October 10th, 2016|Read More
West Makes Investment in NanoPass Technologiesmonimono2017-02-12T12:12:24+00:00April 25th, 2016|Read More